Description: Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Home Page: www.novavax.com
700 Quince Orchard Road
Gaithersburg,
MD
20878
United States
Phone:
240 268 2000
Officers
| Name | Title |
|---|---|
| Mr. John Charles Jacobs M.B.A. | President, CEO & Director |
| Mr. John Joseph Trizzino B.S., M.B.A. | President & COO |
| Mr. James Patrick Kelly C.F.A. | Executive VP, CFO & Treasurer |
| Mr. Mark Casey | Executive VP, Chief Legal Officer & Corporate Secretary |
| Mr. Richard P. Crowley | Executive VP & COO |
| Mr. Troy Morgan Esq., J.D. | Senior VP, Deputy General Counsel & Chief Compliance Officer |
| Ms. Erika S. Trahan | Associate Director of Investor & Public Relations |
| Mr. Ian J. Watkins | Executive VP & Chief Human Resources Officer |
| Ms. Silvia Taylor M.B.A. | Executive VP and Chief Corporate Affairs & Advocacy Officer |
| Dr. Robert Walker M.D. | Senior VP & Chief Medical Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 8.9928 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 72.3201 |
| Price-to-Sales TTM: | 1.629 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 1543 |